APMD — Q2 2026 Financial Report Analysis

Overview

Apnimed, a drug developer that IPO'd on Nasdaq on July 31, 2026, reported net income of $125.9 million for the quarter ended June 30, 2026. A year earlier it lost $69.5 million. The profit did not come from selling anything. Apnimed has no approved product. Two one-time accounting gains totalling $142.5 million produced it. The first came from selling its stake in its sleep-drug joint venture with Shionogi. The second came from writing off a $57.1 million liability tied to an old Shionogi agreement that Apnimed ended. Without those gains, the business lost money as you would expect: an operating loss of $11.7 million, with spending moving from clinical trials to launch preparation. Everything now depends on one date. The FDA has accepted Apnimed's application for AD109, a once-nightly pill for obstructive sleep apnea (OSA) with the proposed name Oxnimbi, and its target decision date (the "PDUFA date") is February 28, 2027.

At a glance

• $125.9M net income, but about -$16.6M without the one-offs. The $85.4M gain on the joint-venture sale and the $57.1M liability reversal are non-recurring. Take them out and the quarter was a loss.
• $172.8M cash at June 30, plus $200.4M net from the August IPO. Management says this pays for operations "through June 2028", which covers the February 2027 FDA decision and more than a year after it.
• G&A spending up 137% to $12.7M, while R&D fell 38% to $9.9M. Apnimed's spending is shifting from running trials to preparing to sell a drug.

The numbers

n/m = not meaningful. A percentage change from a loss to a profit has no useful reading.

Where the "revenue" comes from, and why it is ending

Apnimed has never sold a product. Its revenue line is payment for R&D work it did for Shionogi-Apnimed Sleep Science (SASS), the joint venture it formed with Japanese drugmaker Shionogi in 2023. Most of that payment was received upfront and booked as revenue gradually as the work was done. Q2 revenue fell to $12.1M from $17.1M. The 10-Q puts this "primarily" down to less R&D work for SASS "due to the winding down of the RESTEADY trial."

The bigger effect shows up in the half-year total. Six-month revenue was $96.9M against $20.2M, and $81.3M of it was a one-time "cumulative catch-up": an accounting adjustment that books in one go revenue that would otherwise have been spread out. It happened because selling the SASS stake cut the remaining work Apnimed expected to do. No new cash came in for it. The revenue had been sitting on the balance sheet as deferred revenue, which dropped from $113.1M to $19.5M over the half. With the JV sold, investors should expect this revenue line to shrink toward zero. Apnimed's future revenue depends on Oxnimbi being approved.

Spending: from trials to launch preparation

• R&D fell to $9.9M from $16.0M. Direct Oxnimbi trial costs dropped to $2.8M from $10.4M (-73%) "as LunAIRo and SynAIRgy trials were completed in 2025". Those were the two Phase 3 studies behind the FDA application. Medical affairs spending rose to $2.4M from $0.9M because of more engagement with key opinion leaders, meaning the sleep specialists who influence prescribing.
• G&A more than doubled to $12.7M from $5.4M. The filing lists $4.0M on launch "infrastructure" (education on unmet need in OSA, pricing strategy, market-access planning, brand positioning), $3.0M more on legal services and salaries for new hires, and $0.3M more stock-based compensation. The 10-Q expects G&A to "increase substantially" with commercialization and with the costs of being a public company.

What the headline numbers hide

• The profit is almost entirely one-offs. Q2 "other income" was $137.8M. It consisted of an $85.4M gain on selling the SASS stake (sold April 6 for $100M upfront, plus a possible $50M milestone and royalties of mid-to-low single digits) and a $57.1M gain from reversing a deposit liability. That liability was cash Shionogi paid in 2023 for a right of first negotiation on certain Apnimed drug candidates. Apnimed ended that agreement in April 2026 without a deal, so the money it had already received no longer counts as owed. Neither gain will recur.
• Cash flow tells the real story. Over six months, net income was $193.7M while operating cash flow was -$37.9M. The gap comes from non-cash items: the $85.4M sale gain, a $93.5M drawdown of deferred revenue and the $57.1M deposit reversal. The actual cash came from investing and financing: $100M from the SASS sale, a $50M term loan, and a $25M preferred stock round.
• The EPS figure won't be comparable next quarter. Basic EPS was $26.25 and diluted EPS $3.91. They differ this much because, before the IPO, only about 4.8 million common shares existed, while the diluted count of 32.4 million includes preferred shares that had not yet converted. After the IPO (13.8 million new shares at $16), the preferred conversion and the conversion of $35M of convertible notes into 2.6 million shares, the share count is much larger. Per-share comparisons across the IPO are not meaningful.
• New debt brings new costs and restrictions. The April credit facility with HealthCare Royalty Partners is up to $150M. $50M has been drawn, at three-month SOFR (a benchmark interest rate) plus 5.75%. It also includes a "revenue interest", which gives the lender a share of future sales, valued at $10.0M. Setting it up created $2.7M of other expense (mostly issuance costs) and $2.1M of losses from fair-value changes on the loan and revenue interest this quarter. Apnimed must also keep at least $20M of cash in pledged accounts. A further $50M (Tranche B) is only available if the FDA approves Oxnimbi by June 30, 2027. Another $50M (Tranche C) requires trailing 12-month net sales of at least $175M by mid-2028.
• Stockholders' deficit is a pre-IPO accounting artifact. The balance sheet showed a $176.2M stockholders' deficit at June 30. This is because $245.9M of convertible preferred stock sat outside equity. Those shares converted at the IPO, so it does not indicate distress.

Takeaway: Apnimed's first reported quarter shows a $125.9M profit, but none of it came from running the business. Two one-time gains from unwinding its Shionogi relationship produced it, and those same moves also remove its only revenue source. Strip them out and Apnimed is a pre-revenue company burning about $19M of cash a quarter, with roughly $373M of cash (June 30 balance plus net IPO proceeds) to get through a single FDA decision on February 28, 2027.

What to watch next

• The February 28, 2027 FDA decision on Oxnimbi. If approved, Oxnimbi would be the first oral drug targeting the muscle-control cause of upper-airway collapse in OSA. It combines aroxybutynin, a new drug that blocks the nerve signal acetylcholine, with atomoxetine, an existing drug that raises the brain chemical norepinephrine. The 10-Q flags a combination-specific risk: the FDA could require a "factorial trial" showing that each of the two ingredients adds to the effect. Apnimed says it has given the FDA data suggesting neither ingredient alone works as well as the pair. It also notes that atomoxetine's existing label carries a boxed warning (for suicidal thinking in children and adolescents) and liver and cardiovascular warnings, which could shape Oxnimbi's label.
• How fast G&A rises. At about $19M a quarter of operating cash burn, a "through June 2028" runway leaves room for a much bigger launch budget. Watch whether quarterly G&A keeps climbing from $12.7M as Apnimed hires a sales force ahead of approval.
• Manufacturing readiness. Apnimed relies on one contract manufacturer for Oxnimbi. That manufacturer previously received FDA inspection findings (a Form 483), which the company says have been resolved. Problems at the plant could delay a launch even if the drug is approved.
• Our read: Financially, the next two quarters should be simple: very little revenue, an operating loss in the mid-to-high teens of millions, and a cash balance that started Q3 near $373M. The fundraising has removed money as a near-term risk. Whether Apnimed has any business beyond 2027 depends on the FDA's decision and the label it grants.

This report is based on Apnimed's Form 10-Q for the quarter ended June 30, 2026, filed September 8, 2026, and the accompanying earnings release.